直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 113603
タイトル別表記
ANTITUMOUR EFFECT OF VALPROIC ACID AGAINST SALIVARY GLAND CANCER
著者
永井, 宏和 The University of Tokushima KAKEN研究者をさがす
小林, 真左子 The University of Tokushima KAKEN研究者をさがす
大江, 剛 The University of Tokushima KAKEN研究者をさがす
Hara, Kanae The University of Tokushima
内田, 大亮 The University of Tokushima KAKEN研究者をさがす
玉谷, 哲也 The University of Tokushima KAKEN研究者をさがす
藤澤, 健司 The University of Tokushima KAKEN研究者をさがす
キーワード
valproic acid
salivary gland cancer
antitumour activity
epigenetics
histone deacetylase inhibitor
資料タイプ
学術雑誌論文
抄録
Salivary gland cancer (SGC) has a comparatively poor prognosis and is prone to frequent recurrence and metastases. Therefore, the development of more effective chemotherapy against SGC is desirable. The aim of the present study was to investigate the antitumour effects of valproic acid (VPA) against SGC in vitro and in vivo. Two human SGC cell lines (HSY and HSG cells) were used in the present study. The effects of VPA on the proliferation of SGC cells in vitro were assessed by MTT assay. Cancer cells treated with VPA were subjected to cell cycle analysis by flow cytometry. In addition, the expression levels of p21 and p27 were examined by real-time RT-PCR to identify the mechanisms of the antitumour effect of VPA on SGC. The effects of VPA on cancer growth in vivo were evaluated in a xenograft model. VPA inhibited the proliferation of SGC cells in a dose-dependent manner in vitro. Degenerated cancer cells were observed at high concentrations of VPA. In the cell cycle analysis, VPA induced cell-growth inhibition and G1 arrest of cell cycle progression in both cancer cell lines in a time-and dose-dependent manner. VPA markedly upregulated the mRNA expression levels of both p21 and p27 in both SGC cell lines in a time-dependent manner. In the xenograft model experiment, VPA treatment markedly inhibited the growth of salivary gland tumours when compared with the growth of the untreated controls. VPA may be a valuable drug in the development of better therapeutic regimens for SGC.
掲載誌名
Oncology Reports
ISSN
1021335X
17912431
cat書誌ID
AA11016405
出版者
Spandidos Publications
31
3
開始ページ
1453
終了ページ
1458
発行日
2013-12-31
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
歯学系
病院